Protalix Biotherapeutics, Inc. (PLX)
2.74
+0.01
(+0.37%)
USD |
NYAM |
Oct 07, 13:51
Protalix Biotherapeutics Enterprise Value : 187.79M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 187.79M |
| October 05, 2026 | 186.18M |
| October 02, 2026 | 186.18M |
| October 01, 2026 | 183.76M |
| September 30, 2026 | 190.21M |
| September 29, 2026 | 184.57M |
| September 28, 2026 | 184.57M |
| September 25, 2026 | 186.99M |
| September 24, 2026 | 189.40M |
| September 23, 2026 | 193.43M |
| September 22, 2026 | 196.65M |
| September 21, 2026 | 189.40M |
| September 18, 2026 | 184.57M |
| September 17, 2026 | 185.37M |
| September 16, 2026 | 183.76M |
| September 15, 2026 | 182.15M |
| September 14, 2026 | 191.01M |
| September 11, 2026 | 180.54M |
| September 10, 2026 | 187.79M |
| September 09, 2026 | 182.96M |
| September 08, 2026 | 181.35M |
| September 04, 2026 | 182.96M |
| September 03, 2026 | 178.93M |
| September 02, 2026 | 176.51M |
| September 01, 2026 | 176.51M |
| Date | Value |
|---|---|
| August 31, 2026 | 174.90M |
| August 28, 2026 | 172.48M |
| August 27, 2026 | 178.12M |
| August 26, 2026 | 167.65M |
| August 25, 2026 | 161.20M |
| August 24, 2026 | 162.01M |
| August 21, 2026 | 159.59M |
| August 20, 2026 | 159.59M |
| August 19, 2026 | 157.17M |
| August 18, 2026 | 156.37M |
| August 17, 2026 | 152.34M |
| August 14, 2026 | 146.70M |
| August 13, 2026 | 157.98M |
| August 12, 2026 | 178.93M |
| August 11, 2026 | 163.62M |
| August 10, 2026 | 167.65M |
| August 07, 2026 | 166.04M |
| August 06, 2026 | 164.43M |
| August 05, 2026 | 164.43M |
| August 04, 2026 | 158.79M |
| August 03, 2026 | 154.76M |
| July 31, 2026 | 158.79M |
| July 30, 2026 | 150.73M |
| July 29, 2026 | 150.73M |
| July 28, 2026 | 155.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Altimmune, Inc. | 228.94M |
| Taysha Gene Therapies, Inc. | 1.030B |
| Humacyte, Inc. | 118.92M |
| Agenus, Inc. | 583.85M |
| Amgen, Inc. | 260.96B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.777M |
| Revenue (Quarterly) | 19.90M |
| Total Expenses (Quarterly) | 16.12M |
| EPS Diluted (Quarterly) | 0.0458 |
| Gross Profit Margin (Quarterly) | 60.99% |
| Profit Margin (Quarterly) | 18.98% |
| Earnings Yield | 8.29% |
| Operating Earnings Yield | 10.40% |
| Normalized Earnings Yield | 8.285 |